CCNE1 and PLK1 Mediate Resistance to Palbociclib in HR+/HER2− Metastatic Breast Cancer

Ángel Guerrero‐Zotano; Stefania Belli; Christoph Zielinski; Miguel Gil‐Gil; Antonio Fernández‐Serra; Manuel Ruíz-Borrego; Eva Ciruelos; Javier Pascual; Montserrat Muñoz-Mateu; Begoña Bermejo; Mireia Margelí Vila; Antonio Antón; Laura Murillo; Bella Nissenbaum; Yuan Liu; Jesús Herránz; Daniel Fernández-García; Rosalía Caballero; José Antonio López‐Guerrero; Roberto Bianco; Luigi Formisano; Nicholas C. Turner; Miguel Martín

doi:10.1158/1078-0432.ccr-22-2206

Ask about this paper

Answers are grounded in this paper and cite their sources.

Abstract

We confirm the association of non-luminal subtype and CCNE1 with resistance to CDK4/6i+ET in HR+ MBC. High levels of PLK1 mRNA identify patients with poor response to palbociclib, suggesting PLK1 could also play a role in the setting of resistance to CDK4/6i.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Guerrero‐Zotano et al. (2023) studied this question.

synapsesocial.com/papers/69d77210b1cb92dd1bb8b3c3 https://doi.org/10.1158/1078-0432.ccr-22-2206

View Full Paper

Ask AI

Bookmark

Share

CCNE1 and PLK1 Mediate Resistance to Palbociclib in HR+/HER2− Metastatic Breast Cancer

Ask about this paper

Abstract

Discussion

Cite This Study

CCNE1 and PLK1 Mediate Resistance to Palbociclib in HR+/HER2− Metastatic Breast Cancer

Ask about this paper

Abstract

Discussion

Cite This Study

Keep reading

Keep reading